Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

NCT03221400 is registered in ClinicalTrials.gov with Tarveda Therapeutics as lead sponsor.

NCT NCT03221400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03221400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
Lead sponsor
Tarveda Therapeutics
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 29, 2017
Completion date
June 30, 2023
Enrollment
340 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, advanced cancer, carcinoma, endometrial adenocarcinoma, gastric adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, neoplasms, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, small cell lung carcinoma, small-cell lung cancer, solid carcinoma, solid tumor, squamous cell carcinoma, squamous cell carcinoma of the anus, squamous cell carcinoma of the cervix, squamous cell carcinoma of the penis, squamous cell carcinoma of the vulva